R720 Pill - blue round, 10mm
Pill with imprint R720 is Blue, Round and has been identified as Lamotrigine Extended-Release 200 mg. It is supplied by Dr. Reddy's Laboratories, Inc.
Lamotrigine is used in the treatment of Bipolar Disorder; Lennox-Gastaut Syndrome; Seizure Prevention; Epilepsy; Seizures and belongs to the drug class triazine anticonvulsants. Risk cannot be ruled out during pregnancy. Lamotrigine 200 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for R720
Lamotrigine Extended-Release
- Imprint
- R720
- Strength
- 200 mg
- Color
- Blue
- Size
- 10.00 mm
- Shape
- Round
- Availability
- Prescription only
- Drug Class
- Triazine anticonvulsants
- Pregnancy Category
- C - Risk cannot be ruled out
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Dr. Reddy's Laboratories, Inc.
- National Drug Code (NDC)
- 55111-0720
- Inactive Ingredients
-
hypromelloses,
ferrosoferric oxide,
lactose monohydrate,
magnesium stearate,
polyethylene glycol 400,
magnesium silicate,
titanium dioxide,
triethyl citrate,
shellac,
methacrylic acid - ethyl acrylate copolymer (1:1) type a,
FD&C Blue No. 2
Note: Inactive ingredients may vary.
Related images for "R720"
More about lamotrigine
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1,845)
- Drug images
- Latest FDA alerts (6)
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- Drug class: triazine anticonvulsants
- Breastfeeding
- En español
Patient resources
- Lamotrigine drug information
- Lamotrigine Chewable Dispersible Tablets
- Lamotrigine Extended-Release Tablets
- Lamotrigine Orally Disintegrating Tablets
Other brands
Lamictal, Lamictal XR, Subvenite, Lamictal ODT, Lamictal CD
Professional resources
- Lamotrigine monograph
- Lamotrigine (FDA)
- Lamotrigine Chewable Tablet (FDA)
- Lamotrigine Extended Release Tablet (FDA)
- Lamotrigine ODT (FDA)
Other brands
Lamictal, Lamictal XR, Subvenite
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.